Last reviewed · How we verify

NCT04458155

Li-Hep vs. Non-Li-Hep Coated Transfer Device

Completed Last updated 10 June 2022
What this trial tests

trial testing Siemens® Point-of-care high sensitive troponin I analyzer in Acute Coronary Syndrome in 70 participants. Completed in 1 April 2021.

Timeline
18 June 2020
Primary endpoint
19 December 2020
1 April 2021

Quick facts

Lead sponsorVieCuri Medical Centre
StatusCompleted
Study typeOBSERVATIONAL
Enrollment70
Start date18 June 2020
Primary completion19 December 2020
Estimated completion1 April 2021
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

VieCuri Medical Centre

Who can join

18 and older, any sex, with Acute Coronary Syndrome or Chest Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, diagnostic, cohort study within the standard care of acute coronary syndrome (ACS) patients. It compares the analytical performance of Siemens® point-of-care high sensitive troponin I testing in venous, plasma and capillary sample types. The investigators hypothesize that there is a good correlation between the Siemens® POC HS cTnI assay results for the three sample types and that the bias between different POC sample types reduces from \~10% to ≤ 5% when using heparinized transfer device for the capillary sample.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Coronary Syndrome

Currently open trials in the same condition.

Other VieCuri Medical Centre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04458155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing